The acute effect of 2-bromo-a-ergocryptine (CB-154) on anterior pituitary hormones and free fatty acids in man.
CB-154 was administered to six healthy subjects in three different single doses - 1 mg, 2,5 mg, and 3 mg. Growth hormone, prolactin, follicle stimulating hormone, luteinizing hormone, cortisol, blood sugar and free fatty acids were determined. 2.5 and 3 mg doses of CB-154 induced a significant rise in growth hormone and free fatty acids, while prolactin decreased. In addition, CB-154 prevented the circadian fall of plasma cortisol. There were no changes in follicle stimulating hormone, luteinizing hormone or blood sugar levels.
D001786:Blood Glucose / Q000032:analysis; D001971:Bromocriptine / Q000494:pharmacology*; D004873:Ergolines / Q000494:pharmacology*; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008053:Lipid Mobilization / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010908:Pituitary Hormones, Anterior / Q000097:blood*; D011388:Prolactin / Q000097:blood
D001786:Blood Glucose; D004873:Ergolines; D005230:Fatty Acids, Nonesterified; D010908:Pituitary Hormones, Anterior; D001971:Bromocriptine; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D006854:Hydrocortisone